Comparative evaluation of uricodepressants allopurinol and febuxostat in gouty nephropathy. Message 1. Сlinical study


  • D.D. Ivanov Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • O.V. Sinyachenko Donetsk National Medical University, Lyman, Ukraine
  • T.B. Bevzenko Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • D.M. Fedorov Donetsk National Medical University, Lyman, Ukraine



gout, nephropathy, uricodepressive therapy, efficacy, allopurinol, febuxostat


Background. Renal damage is an almost constant symptom of gout, which determines the prognosis of the dise­ase. Hyperuricemia in gouty nephropathy belongs to independent risk factors for deterioration of the nitrogen and electrolyte excretory function of the kidneys. The purpose of the study was a comparative evaluation of the effect of uricodepressants allopurinol and febuxostat on the functional state of the kidneys in patients with gout. Materials and methods. Seventy three patients with primary gout (men with an average age of 49 years and disease duration of 10 years) were examined. The chronic form of arthritis was diagnosed in 71 % of cases, the intermittent one — in 29 %, peripheral tofi were detected in 53 % of patients. Chronic kidney disease stage I, II, III and IV was diagnosed at a ratio of 56 : 12 : 2 : 1, latent, urolytic and proteinuric types of gouty nephropathy — in 53, 37, 10 % of cases, arterial hypertension — in 47 %. Hyperuricemia at the time of examination was found in 84 % of patients, hyperuricuria — in 52 %, metabolic, renal and mixed types of hyperuricemia occurred in 57; 3 and 40 % of cases, respectively. Results. Comparative evaluation of allopurinol, a xanthine oxidase inhibitor, and febuxostat, a xanthine oxidoreductase inhibitor, in terms of kidney function in patients with gouty nephropathy, showed that the latter should be preferred, although the hypouricemic effect of both uricodepressants is approximately the same, and the initial indices of viscoelasticity of urine and β2-microglobulinuria are prognostic criteria for the efficacy of allopurinol and febuxostat therapy, respectively. Conclusions. In the future, it will be useful to determine the morphological changes in the kidneys in experimental gouty nephropathy under the influence of allopurinol and febuxostat, and it is also advisable to evaluate the results of combined use of uricodepressants with other groups of hy­pouricemic agents (uricosuric drugs, pegloticase enzyme, etc.).


Download data is not yet available.


Becker MA, MacDonald PA, Hunt B, Gunawardhana L. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1011-7. doi: 10.1080/15257770.2011.603715.

Crittenden DB, Pillinger MH. New therapies for gout. Annu Rev Med. 2013;64(1):325-37. doi: 10.1146/annurev-med-080911-105830.

Dalbeth N, Fransen J, Jansen TL, Neogi T, Schumacher HR, Taylor WJ. New classification criteria for gout: a framework for progress. Rheumatology (Oxford). 2013 Oct;52(10):1748-53. doi: 10.1093/rheumatology/ket154.

Dubreuil M, Neogi T, Chen CA, Choi HK, Chaisson CE, Hunter DJ, Zhang Y. Increased risk of recurrent gout attacks with hospitalization. Am J Med. 2013 Dec;126(12):1138-41.e1. doi: 10.1016/j.amjmed.2013.06.026.

Edwards NL. Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford). 2009 May;48 Suppl 2:ii15-ii19. doi: 10.1093/rheumatology/kep088.

Fang ZH, Waizy H. Current concepts in the treatment of gouty arthritis. Orthop Surg. 2013 Feb;5(1):6-12. doi: 10.1111/os.12024.

Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, Tonelli M. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum. 2013 Dec;43(3):367-75. doi: 10.1016/j.semarthrit.2013.05.004.

Hiramitsu S, Ishiguro Y, Matsuyama H, et al. Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems. Clin Exp Hypertens. 2014;36(6):433-40. doi: 10.3109/10641963.2013.846358.

Humbert A, Stucker F. Acid uric: key player in a recently recognized devastating nephropathy and in the development of chronic kidney disease. Rev Med Suisse. 2018 Feb 21;14(595):414-417. (in French).

Juge PA, Truchetet ME, Pillebout E, et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2017 Oct;84(5):595-598. doi: 10.1016/j.jbspin.2016.09.020.

Juraschek SP, Kovell LC, Miller ER, Gelber AC. Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010. Semin Arthritis Rheum. 2013 Jun;42(6):551-61. doi: 10.1016/j.semarthrit.2012.09.009.

Kabul S, Shepler B. A review investigating the effect of allopurinol on the progression of kidney disease in hyperuricemic patients with chronic kidney disease. Clin Ther. 2012 Dec;34(12):2293-6. doi: 10.1016/j.clinthera.2012.10.008.

Kamatani N, Fujimori S, Hada T, et al. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S50-6. doi: 10.1097/RHU.0b013e31822541d0.

Kiadaliri AA, Uhlig T, Englund M. Burden of gout in the Nordic region, 1990-2015: findings from the Global Burden of Disease Study 2015. Scand J Rheumatol. 2018 Jan 29:1-8. doi: 10.1080/03009742.2017.1405461.

Kim S, Kim HJ, Ahn HS, et al. Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis. Kidney Res Clin Pract. 2017 Sep;36(3):274-281. doi: 10.23876/j.krcp.2017.36.3.274.

Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease. J Clin Pharm Ther. 2013 Jun;38(3):258-61. doi: 10.1111/jcpt.12057.

Kuo CF, Grainge MJ, See LC, et al. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther. 2015 Jan 23;17:13. doi: 10.1186/s13075-015-0522-8.

Lien YH, Logan JL. Cross-reactions between allopurinol and febuxostat. Am J Med. 2017 Feb;130(2):e67-e68. doi: 10.1016/j.amjmed.2016.08.042.

Luo H, Fang WG, Zuo XX, et al. The clinical characteristics, diagnosis and treatment of patients with gout in China. Zhonghua Nei Ke Za Zhi. 2018 Jan 1;57(1):27-31. doi: 10.3760/cma.j.issn.0578-1426.2018.01.005.

Nakamura M, Fujita K, Toyoda Y, Takada T, Hasegawa H, Ichida K. Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2. Drug Metab Pharmacokinet. 2018 Feb;33(1):77-81. doi: 10.1016/j.dmpk.2017.11.002.

Pascual E, Sivera F, Yasothan U, Kirkpatrick P. Febuxostat. Nat Rev Drug Discov. 2009 Mar;8(3):191-2. doi: 10.1038/nrd2831.

Pascual E, Sivera F, Andrés M. Managing gout in the patient with renal impairment. Drugs Aging. 2018 Apr;35(4):263-273. doi: 10.1007/s40266-018-0517-7.

Perez-Ruiz F. Treatment with allopurinol is associated with lower risk of acute kidney injury in patients with gout: a retrospective analysis of a nested cohort. Rheumatol Ther. 2017 Dec;4(2):419-425. doi: 10.1007/s40744-017-0082-2.

Radak-Perovic M, Zlatkovic-Svenda M. Novelties in gout. Srp Arh Celok Lek. 2013 Jan-Feb;141(1-2):109-15. (in Serbian).

Richette P, Garay R. Novel drug discovery strategies for gout. Expert Opin Drug Discov. 2013 Feb;8(2):183-9. doi: 10.1517/17460441.2013.742061.

Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am. 2014 May;40(2):155-75. doi: 10.1016/j.rdc.2014.01.001.

Ruilope LM, Pontremoli R. Serum uric acid and cardio-renal diseases. Curr Med Res Opin. 2013 Apr;29 Suppl 3:25-31. doi: 10.1185/03007995.2013.790803.

Singh JA, Cleveland JD. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data. Ann Rheum Dis. 2017 Oct;76(10):1669-1678. doi: 10.1136/annrheumdis-2017-211210.

Sivera F, Andres M, Carmona L, Kydd AS, Moi J, Seth R, Sriranganathan M. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014 Feb;73(2):328-35. doi: 10.1136/annrheumdis-2013-203325.

Stamp LK, Chapman PT, Barclay M, et al. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial. Arthritis Res Ther 2017;19(1):283-9. doi: 10.1186/s13075-017-1491-x.

Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev. 2012 Nov 14;11:CD008653. doi: 10.1002/14651858.CD008653.pub2.

Thurston MM, Phillips BB, Bourg CA. Safety and efficacy of allopurinol in chronic kidney disease. Ann Pharmacother. 2013 Nov;47(11):1507-16. doi: 10.1177/1060028013504740.

Treviño-Becerra A. Uric Acid: The unknown uremic toxin. Contrib Nephrol. 2018;192:25-33. doi: 10.1159/000484275.

Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011 Jan;17(1):7-13. doi: 10.1097/RHU.0b013e318204aab4.

Ye P, Yang S, Zhang W, Lv Q, Cheng Q, Mei M et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther. 2013 Feb;35(2):180-9. doi: 10.1016/j.clinthera.2012.12.011.

Zarowitz BJ, O'Shea TE. Demographic and clinical profile of nursing facility residents with gout. Consult Pharm. 2013 Jun;28(6):370-82. doi: 10.4140/TCP.n.2013.370.



How to Cite

Ivanov, D., Sinyachenko, O., Bevzenko, T., & Fedorov, D. (2021). Comparative evaluation of uricodepressants allopurinol and febuxostat in gouty nephropathy. Message 1. Сlinical study. KIDNEYS, 7(3), 188–195.



Original Articles

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>